TG Therapeutics Inc

TG Therapeutics Inc Stock Forecast & Price Prediction

Live TG Therapeutics Inc Stock (TGTX) Price
$27.17

5

Ratings

  • Buy 5
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$27.17

P/E Ratio

39.56

Volume Traded Today

$4.1M

Dividend

Dividends not available for TGTX

52 Week High/low

27.63/9.81

TG Therapeutics Inc Market Cap

$3.77B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $TGTX ๐Ÿ›‘

Before you buy TGTX you'll want to see this list of ten stocks that have huge potential. Want to see if TGTX made the cut? Enter your email below

TGTX Summary

Based on ratings from 5 stock analysts, the TG Therapeutics Inc stock price is expected to increase by 39.42% in 12 months. This is calculated by using the average 12-month stock price forecast for TG Therapeutics Inc. The lowest target is $9 and the highest is $55. Please note analyst price targets are not guaranteed and could be missed completely.

TGTX Analyst Ratings

About 5 Wall Street analysts have assignedTGTX 5 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect TG Therapeutics Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on TGTX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

TGTX stock forecast by analyst

These are the latest 20 analyst ratings of TGTX.

Analyst/Firm

Rating

Price Target

Change

Date

Tara Bancroft
TD Cowen

Buy

$50

Initiates

Oct 29, 2024
Edward White
HC Wainwright & Co.

Buy

$49

Reiterates

Sep 18, 2024
Mayank Mamtani
B. Riley Securities

Buy

$34

Maintains

Aug 7, 2024
Corinne Jenkins
Goldman Sachs

Neutral

$20

Maintains

Aug 7, 2024
Edward White
HC Wainwright & Co.

Buy

$49

Reiterates

Aug 6, 2024
Matthew Kaplan
Ladenburg Thalmann

Buy

$40

Maintains

May 2, 2024
Edward White
HC Wainwright & Co.

Buy

$49

Maintains

May 2, 2024
Edward White
HC Wainwright & Co.

Buy

$45

Reiterates

Apr 18, 2024
Eric Joseph
JP Morgan

Overweight

$25

Reiterates

Apr 18, 2024
Matthew Kaplan
Ladenburg Thalmann

Buy

$39

Reiterates

Apr 18, 2024
Edward White
HC Wainwright & Co.

Buy

$45

Reiterates

Mar 1, 2024
Corinne Jenkins
Goldman Sachs

Neutral

$13

Maintains

Feb 29, 2024
Edward White
HC Wainwright & Co.

Buy

$45

Reiterates

Feb 28, 2024
Mayank Mamtani
B. Riley Securities

Buy

$29

Maintains

Feb 5, 2024
Edward White
HC Wainwright & Co.

Buy

$45

Maintains

Jan 11, 2024
Matthew Andrews
Jefferies

Buy


Maintains

Nov 1, 2023
Eric Joseph
JP Morgan

Overweight

$23

Maintains

Nov 1, 2023
Mayank Mamtani
B. Riley Securities

Buy

$24

Maintains

Oct 20, 2023
Edward White
HC Wainwright & Co.

Buy

$41

Reiterates

Sep 18, 2023
Eric Joseph
JP Morgan

Overweight

$22

Maintains

Aug 7, 2023

TGTX Company Information

What They Do: Develops treatments for B-cell mediated diseases.

Business Model: The company generates revenue primarily through the commercialization of its therapeutic products, such as BRIUMVI, which is aimed at treating various forms of multiple sclerosis. Additionally, TG Therapeutics has a robust pipeline of investigational medicines, including Umbralisib and TG-1701, which may provide future revenue streams upon successful development and approval.

Other Information: TG Therapeutics has established several license and collaboration agreements with various biotechnology companies to enhance its development capabilities. Founded in 1993 and headquartered in Morrisville, North Carolina, the company's focus on innovative treatments positions it well within the biopharmaceutical industry.
TGTX
TG Therapeutics Inc (TGTX)

When did it IPO

2010

Staff Count

300

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. Michael S. Weiss Esq.

Market Cap

$3.77B

TG Therapeutics Inc (TGTX) Financial Data

In 2023, TGTX generated $233.7M in revenue, which was a increase of 8,290.02% from the previous year. This can be seen as a signal that TGTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$152,000

Revenue From 2021

$6.7M

4,300.66 %
From Previous Year

Revenue From 2022

$2.8M

-58.36 %
From Previous Year

Revenue From 2023

$233.7M

8,290.02 %
From Previous Year
  • Revenue TTM $264.8M
  • Operating Margin TTM 14.8%
  • Gross profit TTM $219.5M
  • Return on assets TTM 3.8%
  • Return on equity TTM 7.9%
  • Profit Margin -5.4%
  • Book Value Per Share 1.24%
  • Market capitalisation $3.77B
  • Revenue for 2021 $6.7M
  • Revenue for 2022 $2.8M
  • Revenue for 2023 $233.7M
  • EPS this year (TTM) $-0.10

TG Therapeutics Inc (TGTX) Latest News

News Image

Sat, 02 Nov 2024

Sentiment - POSITIVE

Source - Investors Business Daily

Summary - Meta and Oracle are among the top five stocks to watch this week, focusing on the artificial intelligence market.

Why It Matters - AI stocks like Meta and Oracle are gaining attention, indicating strong market interest and potential growth, which could influence investment decisions and stock performance.

News Image

Fri, 01 Nov 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - TG Therapeutics, Inc. (NASDAQ: TGTX) will hold a conference call on November 4, 2024, at 8:30 AM ET to discuss Q3 2024 results and the business outlook for the year.

Why It Matters - The upcoming conference call will provide insights into TG Therapeutics' Q3 performance and future business strategy, influencing investor sentiment and stock valuation.

News Image

Fri, 11 Oct 2024

Sentiment - POSITIVE

Source - Investors Business Daily

Summary - Investors are encouraged to explore stocks beyond Nvidia, Apple, and Tesla to identify opportunities for significant earnings growth.

Why It Matters - The mention of excluding major tech stocks like Nvidia, Apple, and Tesla suggests potential opportunities in lesser-known companies with high growth potential, indicating a shift in investment strategy.

News Image

Sun, 22 Sep 2024

Sentiment - POSITIVE

Source - Seeking Alpha

Summary - TG Therapeutics shares reached new 52-week highs, bolstered by favorable Briumvi data at ECTRIMS, despite Roche's FDA approval of Ocrevus Zunovo, which is viewed as a minor growth opportunity.

Why It Matters - TG Therapeutics' stock surge reflects strong Briumvi data, indicating competitive positioning against Ocrevus Zunovo. This could signal growth potential and market confidence in Briumvi's efficacy and safety.

News Image

Wed, 18 Sep 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - BRIUMVI showed an annualized relapse rate of 0.020 in year 5 of treatment, indicating one relapse every 50 years for patients.

Why It Matters - A low annualized relapse rate for BRIUMVI indicates strong efficacy, potentially driving higher demand, boosting sales, and positively impacting the company's stock value.

News Image

Wed, 18 Sep 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - TG Therapeutics presented data at ECTRIMS 2024 showing that BRIUMVI infusions in RMS patients caused only mild reactions, and patients switching from anti-CD20 treatment had successful outcomes.

Why It Matters - Positive trial results for BRIUMVI suggest strong market potential in treating multiple sclerosis, indicating potential revenue growth for TG Therapeutics and enhancing investor confidence.

...

TGTX Frequently asked questions

The highest forecasted price for TGTX is $55 from at .

The lowest forecasted price for TGTX is $9 from from

The TGTX analyst ratings consensus are 5 buy ratings, 0 hold ratings, and 0 sell ratings.